Chris Frampton

Prof. Chris Frampton


Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2019 in Journal of Pain Research
Verified
Journal Article
Open access
PDF file
CACarmen Almansa
Carmen Almansa
CFChris Frampton
Chris Frampton
JVJosé Miguel Vela
José Miguel Vela
SWSteve Whitelock
Steve Whitelock
CPCarlos R Plata-Salamán
Carlos R Plata-Salamán
Pain is highly prevalent, but frequently untreated or under-treated, and health care professionals are faced with a range of treatment challenges. Multimodal therapy is recommended and can be achieved using open combinations (ie, concomitant administration) of individual agents, fixed-dose combinations (FDCs), or multimodal agents (ie, single agents with multiple mechanisms of action). Co-crystallization of active pharmaceutical ingredients (APIs) offers another approach, with the potential to provide drugs with unique properties and advantages for therapeutic applications compared to combinations. API–API co-crystals are single-entity forms that offer a unique possibility of improving the physicochemical properties of both constituent APIs, as well as permitting their synchronous release. Consequently, this may positively impact on their pharmacokinetic (PK) properties and profiles, providing a potential advantage over FDCs and translating into improved clinical efficacy and safety profiles. We report here a revision of the literature concerning API–API co-crystals for the treatment of pain. It becomes apparent that identifying APIs with complementary mechanisms of action that can be adequately co-crystallized in an appropriate molecular ratio applicable for therapeutic use is challenging. In addition, API–API co-crystals normally result in a mere increased exposure of an API without defined clinical benefits (since, to maintain the benefit-risk, the dose needs to be proportionally reduced to adjust for the increased exposure). An exception to this is the co-crystal of tramadol-celecoxib (CTC), that represents a unique concept in co-crystal technology. In CTC neither of its three active components that have complementary mechanisms of action (ie, the two enantiomers of tramadol and celecoxib) show increased exposure levels versus commercially available single-entity reference products, but rather show a change in their PK profile with potential clinical advantages. CTC is in Phase III clinical development for the treatment of pain.

1 January 1999 in Chemical Communications
Verified
Journal Article
Closed access
PDF file
ASAlan Spivey
Alan Spivey
BABenjamin I. Andrews
Benjamin I. Andrews
ABAlan D. Brown
Alan D. Brown
CFChris Frampton
Chris Frampton
The B-Me-(S)-CBS catalysed borane reduction of centrosymmetric bis-N-Boc tetrahydro photodimer 3 has been achieved with virtually complete enantiotopic group selectivity (>97% ee) and in good yield (76%).

1 May 2015 in Inorganica Chimica Acta
Verified
Journal Article
Closed access
APAishakhanam H. Pathan
Aishakhanam H. Pathan
ARAsha K. Ramesh
Asha K. Ramesh
RBRaghavendra Bakale
Raghavendra Bakale
GNGanesh N. Naik
Ganesh N. Naik
HKH.G. Rohit Kumar
H.G. Rohit Kumar
KGKalagouda B. Gudasi
Kalagouda B. Gudasi

1 January 1996 in Journal of the Chemical Society, Perkin Transactions 1
Verified
Journal Article
Closed access
PDF file
ASAlan Spivey
Alan Spivey
ACAlfredo Capretta
Alfredo Capretta
CFChris Frampton
Chris Frampton
FLFinian J. Leeper
Finian J. Leeper
ABAlan R. Battersby
Alan R. Battersby
A novel approach, involving X-ray analysis of a specifically designed racemate, in combination with correlations by circular dichroism, allows the absolute configuration of the spiro lactam 4 to be determined. The outcome is that the enantiomer of this lactam which strongly inhibits uroporphyrinogen III synthase (cosynthetase) has the R-configuration and the implications of this finding are briefly discussed.

1 January 1995 in Journal of the Chemical Society, Chemical Communications
Verified
Journal Article
Closed access
PDF file
ASAlan Spivey
Alan Spivey
ACAlfredo Capretta
Alfredo Capretta
CFChris Frampton
Chris Frampton
FLFinian J. Leeper
Finian J. Leeper
ABAlan R. Battersby
Alan R. Battersby
A novel X-ray analysis, combined with correlations by circular dichroism, has been used to establish the (R)-configuration at the stereocentre in that enantiomer of the spirolactam 4 which strongly inhibits uroporphyrinogen III synthase.

5 April 2017 in CrystEngComm
Verified
Journal Article
Open access
PDF file
CFChris Frampton
Chris Frampton
KKKamal K. Ketuly
Kamal K. Ketuly
HAHapipah B. M. Ali
Hapipah B. M. Ali
AAAinnul H. S. Azizan
Ainnul H. S. Azizan
JGJames H. Gall
James H. Gall
DMDavid D. MacNicol
David D. MacNicol
The structure of the iso-propanol clathrate of 4-p-hydroxyphenyl 2,2,4-trimethylthiachroman, the direct thia-analogue of Dianin's compound, has been studied by single-crystal X-ray diffraction as a function of temperature from 371 K down to 90 K. The standard Dianin unit cell, observed at high temperature, undergoes two sequential commensurate thermal phase transformations which results at low temperature in a unit cell with 16 times the original volume and with Z′(host) = 16 and Z = 288, the space group R being retained. This ultimate unit cell with a quadrupled a-axis has a = 111.7910(5) Å and c = 10.8568(1) Å and the crystal packing now features not only the prototypal [OH]6 hexamer host unit but also novel hydrogen-bonded octameric host–guest units with respective symmetries Ci and C1. In addition it has been established that the corresponding achiral selena-Dianin's clathrate and the polar chiral quasiracemic iso-propanol clathrate, space group R3, formed from R-Dianin's and S-thia-Dianin's components also exhibit novel related temperature-dependant behaviour.